---
title: "Heidi Overton FDA Nomination Withdrawn; Merck Stops Nemtabrutinib Program"
id: "stat-news-2-stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss"
published_at: "2026-11-18T14:26:04.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Heidi Overton FDA Nomination Withdrawn; Merck Stops Nemtabrutinib Program
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss)
- **Published At:** 2026-11-18T14:26:04.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The White House withdrew the nomination of **Heidi Overton** to lead the **FDA** after concerns she lacked sufficient Senate support; the administration pulled the bid amid GOP reservations that would have complicated confirmation. - Senate health committee timing was set for a Wednesday vote, and Senator Bill Cassidy indicated Overton had enough backing to clear the committee and win confirmation, according to the source. - Some Republican senators opposed Overton because of her prior positions: backing scaled-back vaccine recommendations, loosening vape restrictions, and stances on abortion policy; these policy concerns were cited as reasons for limited support. - Merck announced it will stop development of its experimental blood cancer drug **nemtabrutinib** after an independent monitoring committee judged that benefits may not outweigh risks in a late-stage study, per Reuters reporting cited in the source. - The company said its own review of the full data confirmed the committee’s finding and that the decision ends a broader development program for chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials. - Nemtabrutinib is an oral agent that targets **BTK**, a protein involved in growth of malignant B cells; the source reported no dosing, patient numbers, or specific efficacy and safety data from the trials. - A GSK lung cancer drug received FDA approval, and the source characterized the approval as further validation of GSK’s acquisition of **Nuvalent**; the article did not provide trial details or the drug’s label specifics. - The source did not report additional trial methodology, numerical results, demographic breakdowns, or regulatory timelines beyond the items summarized above.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss) [FDA](https://www.statnews.com/topic/fda/) [Congress](https://www.statnews.com/topic/congress/) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT@JPM27](https://www.statnews.com/jpm-conference-stat-events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more ## GSK lung cancer drug wins FDA approval, further validating its acquisition of Nuvalent * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Nov. 18, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cuppa stimulation. Our choice today is ginger peach turmeric. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. We appreciate feedback, tips, and criticism. … **The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate** , [STAT](https://www.statnews.com/2026/11/17/heidi-overton-fda-commissioner-nomination-withdrawn/) notes. The Senate’s health panel had been expected to vote on her nomination Wednesday, and the panel’s leader, Sen. Bill Cassidy (R-La.), said on Tuesday that Overton had enough support to clear his committee and win confirmation. But some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy. Advertisement **Merck plans to stop development of its experimental blood cancer drug, nemtabrutinib, after a ​review found the benefits may not outweigh the ‌risks** , [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/merck-stops-trials-blood-cancer-drug-after-risk-assessment-2026-11-17/) says. An independent monitoring committee reached that conclusion after reviewing results from a late-stage study and Merck said its review of the full ​data confirmed the finding. The decision ends a broader development program ​for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, ​including two other late-stage trials. Nemtabrutinib is an oral drug designed to block BTK, a ​protein that helps ​cancerous B ⁠cells grow. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AP26267614794641-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [White House pulls nomination of Heidi Overton to lead FDA](https://www.statnews.com/2026/11/17/heidi-overton-fda-commissioner-nomination-withdrawn/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_331634765-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After death in gene therapy trial for a brain disease, progress is reported](https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1493311578-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Updated health data privacy rule sets standards for sharing records with apps](https://www.statnews.com/2026/11/17/hipaa-privacy-rule-update-aims-to-improve-patient-access-to-records/) 5. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 2. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 4. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 17, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more ](https://www.statnews.com/pharmalot/2026/11/17/roche-breast-cancer-pill-obesity-drugs-in-children/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns ](https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 16, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more ](https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investmen
## Related Clinical Research

- [Flagship opens biotech-creation outpost in the U.K.; sector updates on Isomorphic and Sellas](https://medichelpline.com/clinical-feed/stat-news-1-stat-flagship-opens-biotech-creation-outpost-in-the-u-k.md)
- [Sellas’ galinpepimut-S cut mortality by 41% in Phase 3 AML trial, company reports](https://medichelpline.com/clinical-feed/stat-news-2-stat-sellas-experimental-blood-cancer-immunotherapy-reduced-risk-of-death-in.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.